Home > Publications Database > Differentiation Between Early and Severe Stages of Dementia in Claims Data Based on Diagnosis, Prescription, and Utilization Patterns. > print

001     280975
005     20250918102645.0
024 7 _ |a 10.1007/s40120-025-00778-y
|2 doi
024 7 _ |a pmid:40504345
|2 pmid
024 7 _ |a pmc:PMC12255591
|2 pmc
024 7 _ |a 2193-6536
|2 ISSN
024 7 _ |a 2193-8253
|2 ISSN
037 _ _ |a DZNE-2025-01057
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Platen, Moritz
|0 P:(DE-2719)9001238
|b 0
|e First author
245 _ _ |a Differentiation Between Early and Severe Stages of Dementia in Claims Data Based on Diagnosis, Prescription, and Utilization Patterns.
260 _ _ |a Heidelberg [u.a.]
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1756891649_1280
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Claims data typically lack clinical parameters such as dementia severity, limiting insights into disease progression and related healthcare utilization and costs. Although diagnoses, prescriptions, and utilization patterns may serve as proxies, their validity is unclear. This study aimed to identify and validate these parameters to distinguish early from severe dementia stages.Baseline data from 737 patients with dementia were analyzed. Dementia severity was assessed using the Mini-Mental State Examination and classified as early (≥ 27), mild (20-26), and moderate to severe (0-19). Healthcare utilization was recorded via structured interviews. Diagnoses, long-term care levels, and prescribed medications were extracted from physicians' files. Ordinal logistic regression evaluated associations between predictors and severity, with average marginal effects (AME) quantifying impact. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were computed for key predictors.Among the sample (56% female patients, mean age 80), 18% were in the early stages, 43% mild, and 39% moderate to severe. Antipsychotic prescriptions (odds ratio (OR) 3.40, 95% confidence interval (CI) 1.94-5.95), antidementia drugs (OR 2.31, 95% CI 1.56-3.40), and higher long-term care levels (OR 5.59, 95% CI 2.23-13.99 for level ≥ 4) were associated with advanced severity. AME analysis revealed that antipsychotic use reduced early-stage probability by 14% and increased severe-stage probability by 21%. Similarly, antidementia drugs lowered early-stage probability by 9% and raised severe-stage probability by 13%. Increasing care levels were associated with a 2-16% decline in early-stage probability and a 3-34% rise in severe-stage probability. The combined model showed high specificity (99.6%) and PPV (84.6%) for severe dementia, but sensitivity and NPV for early stage were low.Antidementia drugs, antipsychotics, and long-term care level serve as robust predictors of moderate to severe dementia, whereas early-stage detection remains challenging. Future studies should validate these markers and explore additional predictors to improve early detection in claims data.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alzheimer’s disease
|2 Other
650 _ 7 |a Antidementia drug treatment
|2 Other
650 _ 7 |a Antipsychotics
|2 Other
650 _ 7 |a Claims data
|2 Other
650 _ 7 |a Dementia
|2 Other
650 _ 7 |a Dementia severity
|2 Other
650 _ 7 |a Healthcare utilization
|2 Other
650 _ 7 |a Real-world data
|2 Other
650 _ 7 |a Real-world evidence
|2 Other
700 1 _ |a Buchholz, Maresa
|0 P:(DE-2719)9002138
|b 1
|u dzne
700 1 _ |a Rädke, Anika
|0 P:(DE-2719)9001134
|b 2
|u dzne
700 1 _ |a Glaeser, Eva
|0 P:(DE-2719)9003305
|b 3
|u dzne
700 1 _ |a Iskandar, Audrey
|0 P:(DE-2719)9003158
|b 4
|u dzne
700 1 _ |a van den Berg, Neeltje
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Hoffmann, Wolfgang
|0 P:(DE-2719)2000040
|b 6
|u dzne
700 1 _ |a Michalowsky, Bernhard
|0 P:(DE-2719)2810763
|b 7
|e Last author
|u dzne
773 _ _ |a 10.1007/s40120-025-00778-y
|g Vol. 14, no. 4, p. 1589 - 1608
|0 PERI:(DE-600)2682228-3
|n 4
|p 1589 - 1608
|t Neurology and Therapy
|v 14
|y 2025
|x 2193-6536
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280975/files/DZNE-2025-01057.pdf
856 4 _ |u https://pub.dzne.de/record/280975/files/DZNE-2025-01057%20SUP.pdf
856 4 _ |u https://pub.dzne.de/record/280975/files/DZNE-2025-01057%20SUP.pdf?subformat=pdfa
|x pdfa
856 4 _ |u https://pub.dzne.de/record/280975/files/DZNE-2025-01057.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280975
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001238
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9002138
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9001134
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9003305
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)9003158
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 6
|6 P:(DE-2719)2000040
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2810763
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-18
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEUROL THER : 2022
|d 2024-12-18
915 _ _ |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0
|0 LIC:(DE-HGF)CCBYNC4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-04-10T15:42:53Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-04-10T15:42:53Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-18
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-18
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-18
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-18
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-18
920 1 _ |0 I:(DE-2719)5000067
|k AG Michalowsky
|l Patient-Reported Outcomes and Health Economics Research
|x 0
920 1 _ |0 I:(DE-2719)1510600
|k AG Hoffmann
|l Translational Health Care Research
|x 1
920 1 _ |0 I:(DE-2719)1510800
|k AG Thyrian
|l Interventional Health Care Research (IHCR)
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000067
980 _ _ |a I:(DE-2719)1510600
980 _ _ |a I:(DE-2719)1510800
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21